HUTCHMED (China) Limited (HCM)

ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill

Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More

AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

New 3Sixty Insights Analysis Reinforces the Importance of Insperity's HRScale Service-Enabled HR Solution

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data

Workday Named a Leader in Inaugural 2026 Gartner® Magic Quadrant™ for Workforce Management Technology

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal

HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

Workday Named a Leader in 2026 Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Eleventh Consecutive Year

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

Oracle Named a Leader in the 2026 Gartner® Magic Quadrant™ for Supply Chain Management Suites

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets